NEW YORK (GenomeWeb) – GenomeDx announced today that its prostate cancer classifier tests have been approved by the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP).

The approval covers GenomeDx's Decipher Biopsy and Decipher Post-Op tests, which use genomic data to improve clinical decision-making following biopsy or radical prostatectomy, respectively, in men with prostate cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.